• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Companies won ’t share COVID-19 shots, stalling future vaccine research
The U.S. government has tens of millions of unused doses of messenger RNA (mRNA) COVID-19 vaccines, regularly trashing shots as they pass their expiration dates. It’s a dismal reflection on recent vaccine uptake, but it’s also a serious roadblock for scientists testing and developing vaccines that could protect against future variants of SARS-CoV-2—and the next pandemic. Developers need existing vaccines as a benchmark to compare with new candidates. But government contracts with the vaccinemakers, and the companies’ own policies, prohibit the use of the vaccines for research purposes. “At this stage of the ...
Source: ScienceNOW - May 30, 2023 Category: Science Source Type: news

Now in charge, House Republicans launch flurry of investigations
The new Republican majority in the U.S. House of Representatives is preparing to shine a bright light on science—and scientists. This week, it created two investigative panels that will scrutinize the country’s relationship with China and its response to the COVID-19 pandemic. Both committees are expected to grill many prominent scientists and federal research officials on their actions over the past several years. In approach and style, however, they are likely to be very different. The China panel, officially the Select Committee on Strategic Competition between the United States and the Chinese Communist Party,...
Source: Science of Aging Knowledge Environment - January 13, 2023 Category: Geriatrics Source Type: research

A New Lab-Made COVID-19 Virus Puts Gain-of-Function Research Under the Microscope
On October 14, a team of scientists at Boston University released a pre-print study reporting that they had created a version of SARS-CoV-2 combining two features of different, existing strains that boosted its virulence and transmissibility. Scientists and the public raised questions about the work, which refocused attention on such experiments, and prompted the U.S. government to investigate whether the research followed protocols for these kinds of studies. The concerns surround what is known as gain-of-function studies, in which viruses, bacteria, or other pathogens are created in the lab—either intentionally or ...
Source: TIME: Science - October 27, 2022 Category: Science Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

To thwart the next pandemic, ‘swientists’ hunt for flu viruses at U.S. hog shows
.news-article__hero--featured .parallax__element { object-position: 10% 60%; -o-object-position: 10% 60%; } @media (max-width: 991.98px) { .news-article__hero--featured .parallax:before { background: linear-gradient(180deg, rgba(0, 0, 0, 90%), transparent 50%, transparent 85%, rgba(0, 0, 0, 60%) 100%); } .news-article__hero--featured .news-article__hero__info-wrapper { height: 100%; } .news-article__hero--featured .news-article__hero__scroller { bottom: 0; position: absolute; left: calc(50% - 50px); } .parallax__element {} } @media (min-width: 992px) { .news-article__hero--featured .parallax:before { ...
Source: ScienceNOW - October 27, 2022 Category: Science Source Type: news

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
August 17, 2022 – The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development. The collaboration will evaluate whether the novel regimens, which combine registered products and new chemical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with the goal of identifying a regimen suitable for phase 3 develo...
Source: Johnson and Johnson - August 17, 2022 Category: Pharmaceuticals Source Type: news

Insights into HM and PHM fellowship programs
A hospital medicine fellowship combines the best of hospital medicine with the opportunity for physicians to specialize early in their careers.  According to directors of successful programs at the University of California, San Francisco (UCSF), Deaconess Hospital, the Medical College of Wisconsin, and Akron Children’s Hospital, the best fellowship programs benefit the hospital as well as the fellow. These directors shared their ideas on creating and optimizing fellowships, notably in the establishment of pediatric hospital medicine (PHM) programs, which are a relatively new option. Opportunities for enrichment Dr. Fan...
Source: The Hospitalist - February 3, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Career Source Type: research

Decluttering the problem list in electronic health records
CONCLUSION: Our study suggests areas for improvement for problem list maintenance. Further studies into semantic duplication and clinical decision support tools to encourage problem list maintenance and deduplication are needed.PMID:34597358 | DOI:10.1093/ajhp/zxab381
Source: American Journal of Health-System Pharmacy : AJHP - October 1, 2021 Category: Drugs & Pharmacology Authors: Austin R Brown Allison B McCoy Adam Wright Scott D Nelson Source Type: research

What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news

PNR Weekly Digest: March 30, 2021
Items regarding COVID-19 information are indicated with an * In the Dragonfly: *NNLM Covid-19 Symposium. Keynote Speakers Announced. Registration is Open The Network of the National Library of Medicine (NNLM) is excited to announce a new, free virtual symposium focused on addressing the COVID-19 infodemic in our communities. The NNLM Virtual Symposium: Responding to the COVID-19 Infodemic is an opportunity to address misinformation and mistrust, raise awareness about the pandemic, and efforts to combat it. Symposium attendees can expect to come away from the 2-day experience with a better understanding of COVID-19 and shar...
Source: Dragonfly - March 30, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news

Iodine allergy: Common misperceptions.
CONCLUSION: There is a lack of evidence to support cross-reactivity between iodine-containing compounds in so called iodine-allergic individuals. PMID: 33547463 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - February 6, 2021 Category: Drugs & Pharmacology Authors: Wulf NR, Schmitz J, Choi A Tags: Am J Health Syst Pharm Source Type: research

COVID-19 Pandemic and Telehealth: allergy patient perspectives in an urban, academic medical center
This study aims to assess the patient perspective on telehealth technology during the COVID pandemic.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Darshil Patel, Andrea Pappalardo, Vanessa Harmon, Mary Pasquinelli, Julia Trosman, Christine Weldon, Sharmilee Nyenhuis Source Type: research

Johnson & Johnson ’s COVID-19 Vaccine Results Are Better Than They May Sound
Johnson & Johnson’s Janssen Pharmaceutical Companies announced on Jan. 29 that its one-shot COVID-19 vaccine is 66% effective in protecting against disease, but 85% effective against preventing severe disease—results that could make it especially valuable in the effort to vaccinate parts of the world with weak health care systems. By comparison, the vaccines already authorized in the U.S.—one from Moderna and one from Pfizer-BioNTech—each require two doses, spaced three to four weeks apart. Janssen’s vaccine can also be stored in normal refrigerators, unlike Moderna’s and Pfizer-BioN...
Source: TIME: Health - January 29, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Pages: 1  2